Jeremy P. Blaydes
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Jeremy P. Blaydes has a total of 314 co-authors. Here are the top co-authors by number of shared publications:
- Charles N. Birts
Faculty of Medicine, University of Southampton, Southampton General Hospital, Mailpoint 801, South Academic Block, Tremona Road, Southampton, SO16 6YD, United Kingdom
10 shared publications Matthew Darley
Cancer Sciences Unit Faculty of Medicine University of Southampton Southampton Hants UK
10 shared publications- Ali Tavassoli
University of Southampton
7 shared publications D Wynford-Thomas
Cancer Research Campaign Laboratories, Department of Pathology, University of Wales College of Medicine, Heath Park, Cardiff, UK
5 shared publications- Lee Bergman
Somers Cancer Research Building, University of Southampton, MP824 Southampton General Hospital, Southampton SO166YD, United Kingdom
5 shared publications - Timothy James Underwood
School of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, UK
5 shared publications
Latest Publications
- Open Access
- 5 June 2026
- Published by Springer Nature in Cell Death & Disease
- Vol. 17 (1)
DP103 as a critical modulator of Wnt signaling and cancer stemness: implications for precision treatment in triple negative breast cancer
Triple-negative breast cancer (TNBC) is a clinically aggressive subtype lacking targeted therapies, often characterized by hyperactivation of the Wnt/β-catenin signaling pathway and an enriched population of cancer stem cells (CSCs). Here, we identify the DEAD-box RNA helicase DP103 as a novel modulator of Wnt/β-catenin signaling in TNBC, acting independently of its canonical helicase function. DP103 expression correlates with increased phosphorylation of LRP6 and nuclear β-catenin accumulation, enhancing Wnt transcriptional activity. Mechanistically, DP103 physically interacts with GSK3β to facilitate post-translational modifications essential for Wnt activation. Notably, DP103 itself is a Wnt target, forming a feedforward loop that sustains oncogenic signaling. Functional studies reveal that DP103 promotes CSC-like traits in TNBC cells, including self-renewal and expression of stemness markers (Nanog, Oct4, Sox2), linking its role in Wnt activation to breast cancer stemness and metastasis. In vivo studies using Drosophila models confirmed the evolutionarily conserved role of Gemin3/DP103 in epithelial transformation, though context-dependent differences were observed. Importantly, we demonstrate that RX-5902, a Wnt pathway inhibitor currently in clinical trials, suppresses DP103 expression and Wnt/β-catenin signaling, reducing TNBC cell viability and mammosphere formation without affecting normal epithelial cells. RX-5902 efficacy was abrogated by DP103 depletion, underscoring DP103’s critical role in mediating drug response. In xenograft models, RX-5902 treatment significantly reduced tumor burden and prolonged survival. Collectively, our findings establish DP103 as a key regulator of Wnt-driven oncogenesis in TNBC and highlight its dual role in promoting CSC traits and therapeutic resistance. These insights position DP103 as a potential biomarker and therapeutic target to disrupt sustained Wnt signaling in TNBC, offering new avenues for precision intervention in this challenging breast cancer subtype.
- 5 June 2026
- Published by Springer Nature in Cell Death & Disease
- Vol. 17 (1)
Open AccessDP103 as a critical modulator of Wnt signaling and cancer stemness: implications for precision treatment in triple negative breast cancer
Triple-negative breast cancer (TNBC) is a clinically aggressive subtype lacking targeted therapies, often characterized by hyperactivation of the Wnt/β-catenin signaling pathway and an enriched population of cancer stem cells (CSCs). Here, we identify the DEAD-box RNA helicase DP103 as a novel modulator of Wnt/β-catenin signaling in TNBC, acting independently of its canonical helicase function. DP103 expression correlates with increased phosphorylation of LRP6 and nuclear β-catenin accumulation, enhancing Wnt transcriptional activity. Mechanistically, DP103 physically interacts with GSK3β to facilitate post-translational modifications essential for Wnt activation. Notably, DP103 itself is a Wnt target, forming a feedforward loop that sustains oncogenic signaling. Functional studies reveal that DP103 promotes CSC-like traits in TNBC cells, including self-renewal and expression of stemness markers (Nanog, Oct4, Sox2), linking its role in Wnt activation to breast cancer stemness and metastasis. In vivo studies using Drosophila models confirmed the evolutionarily conserved role of Gemin3/DP103 in epithelial transformation, though context-dependent differences were observed. Importantly, we demonstrate that RX-5902, a Wnt pathway inhibitor currently in clinical trials, suppresses DP103 expression and Wnt/β-catenin signaling, reducing TNBC cell viability and mammosphere formation without affecting normal epithelial cells. RX-5902 efficacy was abrogated by DP103 depletion, underscoring DP103’s critical role in mediating drug response. In xenograft models, RX-5902 treatment significantly reduced tumor burden and prolonged survival. Collectively, our findings establish DP103 as a key regulator of Wnt-driven oncogenesis in TNBC and highlight its dual role in promoting CSC traits and therapeutic resistance. These insights position DP103 as a potential biomarker and therapeutic target to disrupt sustained Wnt signaling in TNBC, offering new avenues for precision intervention in this challenging breast cancer subtype.
- Open Access
- 3 July 2020
- Published by Wiley in FEBS Letters
- Vol. 594 (18) , 2988-3001
Glycolysis, via NADH‐dependent dimerisation of CtBPs, regulates hypoxia‐induced expression of CAIX and stem‐like breast cancer cell survival
Adaptive responses to hypoxia are mediated by the hypoxia‐inducible factor (HIF) family of transcription factors. These responses include the upregulation of glycolysis to maintain ATP production. This also generates acidic metabolites, which require HIF‐induced carbonic anhydrase IX (CAIX) for their neutralisation. C‐terminal binding proteins (CtBPs) are coregulators of gene transcription and couple glycolysis with gene transcription due to their regulation by the glycolytic coenzyme NADH. Here, we find that experimental manipulation of glycolysis and CtBP function in breast cancer cells through multiple complementary approaches supports a hypothesis whereby the expression of known HIF‐inducible genes, and CAIX in particular, adapts to available glucose in the microenvironment through a mechanism involving CtBPs. This novel pathway promotes the survival of stem cell‐like cancer (SCLC) cells in hypoxia.
- 3 July 2020
- Published by Wiley in FEBS Letters
- Vol. 594 (18) , 2988-3001
Open AccessGlycolysis, via NADH‐dependent dimerisation of CtBPs, regulates hypoxia‐induced expression of CAIX and stem‐like breast cancer cell survival
Adaptive responses to hypoxia are mediated by the hypoxia‐inducible factor (HIF) family of transcription factors. These responses include the upregulation of glycolysis to maintain ATP production. This also generates acidic metabolites, which require HIF‐induced carbonic anhydrase IX (CAIX) for their neutralisation. C‐terminal binding proteins (CtBPs) are coregulators of gene transcription and couple glycolysis with gene transcription due to their regulation by the glycolytic coenzyme NADH. Here, we find that experimental manipulation of glycolysis and CtBP function in breast cancer cells through multiple complementary approaches supports a hypothesis whereby the expression of known HIF‐inducible genes, and CAIX in particular, adapts to available glucose in the microenvironment through a mechanism involving CtBPs. This novel pathway promotes the survival of stem cell‐like cancer (SCLC) cells in hypoxia.
- 5 May 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 13 (630)
p53 is regulated by aerobic glycolysis in cancer cells by the CtBP family of NADH-dependent transcriptional regulators
High rates of glycolysis in cancer cells are a well-established characteristic of many human tumors, providing rapidly proliferating cancer cells with metabolites that can be used as precursors for anabolic pathways. Maintenance of high glycolytic rates depends on the lactate dehydrogenase–catalyzed regeneration of NAD+ from GAPDH-generated NADH because an increased NADH:NAD+ ratio inhibits GAPDH. Here, using human breast cancer cell models, we identified a pathway in which changes in the extramitochondrial-free NADH:NAD+ ratio signaled through the CtBP family of NADH-sensitive transcriptional regulators to control the abundance and activity of p53. NADH-free forms of CtBPs cooperated with the p53-binding partner HDM2 to suppress p53 function, and loss of these forms in highly glycolytic cells resulted in p53 accumulation. We propose that this pathway represents a “glycolytic stress response” in which the initiation of a protective p53 response by an increased NADH:NAD+ ratio enables cells to avoid cellular damage caused by mismatches between metabolic supply and demand.
- 5 May 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 13 (630)
p53 is regulated by aerobic glycolysis in cancer cells by the CtBP family of NADH-dependent transcriptional regulators
High rates of glycolysis in cancer cells are a well-established characteristic of many human tumors, providing rapidly proliferating cancer cells with metabolites that can be used as precursors for anabolic pathways. Maintenance of high glycolytic rates depends on the lactate dehydrogenase–catalyzed regeneration of NAD+ from GAPDH-generated NADH because an increased NADH:NAD+ ratio inhibits GAPDH. Here, using human breast cancer cell models, we identified a pathway in which changes in the extramitochondrial-free NADH:NAD+ ratio signaled through the CtBP family of NADH-sensitive transcriptional regulators to control the abundance and activity of p53. NADH-free forms of CtBPs cooperated with the p53-binding partner HDM2 to suppress p53 function, and loss of these forms in highly glycolytic cells resulted in p53 accumulation. We propose that this pathway represents a “glycolytic stress response” in which the initiation of a protective p53 response by an increased NADH:NAD+ ratio enables cells to avoid cellular damage caused by mismatches between metabolic supply and demand.
- Open Access
- 1 April 2019
- Published by Elsevier in Stem Cell Reports
- Vol. 12 (4) , 728-742
Glycolysis Regulates Human Embryonic Stem Cell Self-Renewal under Hypoxia through HIF-2α and the Glycolytic Sensors CTBPs
- 1 April 2019
- Published by Elsevier in Stem Cell Reports
- Vol. 12 (4) , 728-742
Open AccessGlycolysis Regulates Human Embryonic Stem Cell Self-Renewal under Hypoxia through HIF-2α and the Glycolytic Sensors CTBPs
- 22 January 2019
- Published by Oxford University Press (OUP) in Carcinogenesis
- Vol. 40 (7) , 871-882
Stem cell-like breast cancer cells with acquired resistance to metformin are sensitive to inhibitors of NADH-dependent CtBP dimerization
Altered flux through major metabolic pathways is a hallmark of cancer cells and provides opportunities for therapy. Stem cell-like cancer (SCLC) cells can cause metastasis and therapy resistance. They possess metabolic plasticity, theoretically enabling resistance to therapies targeting a specific metabolic state. The C-terminal binding protein (CtBP) transcriptional regulators are potential therapeutic targets in highly glycolytic cancer cells, as they are activated by the glycolytic coenzyme nicotinamide adenine dinucleotide (NADH). However, SCLC cells commonly exist in an oxidative state with low rates of glycolysis. Metformin inhibits complex I of the mitochondrial electron transport chain; it can kill oxidative SCLC cells and has anti-cancer activity in patients. SCLC cells can acquire resistance to metformin through increased glycolysis. Given the potential for long-term metformin therapy, we have studied acquired metformin resistance in cells from the claudin-low subtype of breast cancer. Cells cultured for 8 weeks in sub-IC50 metformin concentration proliferated comparably to untreated cells and exhibited higher rates of glucose uptake. SCLC cells were enriched in metformin-adapted cultures. These SCLC cells acquired sensitivity to multiple methods of inhibition of CtBP function, including a cyclic peptide inhibitor of NADH-induced CtBP dimerization. Single-cell mRNA sequencing identified a reprogramming of epithelial–mesenchymal and stem cell gene expression in the metformin-adapted SCLC cells. These SCLC cells demonstrated an acquired dependency on one of these genes, Tenascin C. Thus, in addition to acquisition of sensitivity to glycolysis-targeting therapeutic strategies, the reprograming of gene expression in the metformin-adapted SCLC cells renders them sensitive to potential therapeutic approaches not directly linked to cell metabolism.
- 22 January 2019
- Published by Oxford University Press (OUP) in Carcinogenesis
- Vol. 40 (7) , 871-882
Stem cell-like breast cancer cells with acquired resistance to metformin are sensitive to inhibitors of NADH-dependent CtBP dimerization
Altered flux through major metabolic pathways is a hallmark of cancer cells and provides opportunities for therapy. Stem cell-like cancer (SCLC) cells can cause metastasis and therapy resistance. They possess metabolic plasticity, theoretically enabling resistance to therapies targeting a specific metabolic state. The C-terminal binding protein (CtBP) transcriptional regulators are potential therapeutic targets in highly glycolytic cancer cells, as they are activated by the glycolytic coenzyme nicotinamide adenine dinucleotide (NADH). However, SCLC cells commonly exist in an oxidative state with low rates of glycolysis. Metformin inhibits complex I of the mitochondrial electron transport chain; it can kill oxidative SCLC cells and has anti-cancer activity in patients. SCLC cells can acquire resistance to metformin through increased glycolysis. Given the potential for long-term metformin therapy, we have studied acquired metformin resistance in cells from the claudin-low subtype of breast cancer. Cells cultured for 8 weeks in sub-IC50 metformin concentration proliferated comparably to untreated cells and exhibited higher rates of glucose uptake. SCLC cells were enriched in metformin-adapted cultures. These SCLC cells acquired sensitivity to multiple methods of inhibition of CtBP function, including a cyclic peptide inhibitor of NADH-induced CtBP dimerization. Single-cell mRNA sequencing identified a reprogramming of epithelial–mesenchymal and stem cell gene expression in the metformin-adapted SCLC cells. These SCLC cells demonstrated an acquired dependency on one of these genes, Tenascin C. Thus, in addition to acquisition of sensitivity to glycolysis-targeting therapeutic strategies, the reprograming of gene expression in the metformin-adapted SCLC cells renders them sensitive to potential therapeutic approaches not directly linked to cell metabolism.
- Open Access
- 17 January 2019
- Published by Springer Nature in British Journal of Cancer
- Vol. 120 (3) , 356-367
HPV, tumour metabolism and novel target identification in head and neck squamous cell carcinoma
Background Metabolic changes in tumour cells are used in clinical imaging and may provide potential therapeutic targets. Human papillomavirus (HPV) status is important in classifying head and neck cancers (HNSCC), identifying a distinct clinical phenotype; metabolic differences between these HNSCC subtypes remain poorly understood. Methods We used RNA sequencing to classify the metabolic expression profiles of HPV+ve and HPV−ve HNSCC, performed a meta-analysis on FDG-PET imaging characteristics and correlated results with in vitro extracellular flux analysis of HPV−ve and HPV+ve HNSCC cell lines. The monocarboxylic acid transporter-1 (MCT1) was identified as a potential metabolic target and tested in functional assays. Results Specific metabolic profiles were associated with HPV status, not limited to carbohydrate metabolism. There was dominance of all energy pathways in HPV-negative disease, with elevated expression of genes associated with glycolysis and oxidative phosphorylation. In vitro analysis confirmed comparative increased rates of oxidative phosphorylation and glycolysis in HPV-negative cell lines. PET SUV(max) scores however were unable to reliably differentiate between HPV-positive and HPV-negative tumours. MCT1 expression was significantly increased in HPV-negative tumours, and inhibition suppressed tumour cell invasion, colony formation and promoted radiosensitivity. Conclusion HPV-positive and negative HNSCC have different metabolic profiles which may have potential therapeutic applications.
- 17 January 2019
- Published by Springer Nature in British Journal of Cancer
- Vol. 120 (3) , 356-367
Open AccessHPV, tumour metabolism and novel target identification in head and neck squamous cell carcinoma
Background Metabolic changes in tumour cells are used in clinical imaging and may provide potential therapeutic targets. Human papillomavirus (HPV) status is important in classifying head and neck cancers (HNSCC), identifying a distinct clinical phenotype; metabolic differences between these HNSCC subtypes remain poorly understood. Methods We used RNA sequencing to classify the metabolic expression profiles of HPV+ve and HPV−ve HNSCC, performed a meta-analysis on FDG-PET imaging characteristics and correlated results with in vitro extracellular flux analysis of HPV−ve and HPV+ve HNSCC cell lines. The monocarboxylic acid transporter-1 (MCT1) was identified as a potential metabolic target and tested in functional assays. Results Specific metabolic profiles were associated with HPV status, not limited to carbohydrate metabolism. There was dominance of all energy pathways in HPV-negative disease, with elevated expression of genes associated with glycolysis and oxidative phosphorylation. In vitro analysis confirmed comparative increased rates of oxidative phosphorylation and glycolysis in HPV-negative cell lines. PET SUV(max) scores however were unable to reliably differentiate between HPV-positive and HPV-negative tumours. MCT1 expression was significantly increased in HPV-negative tumours, and inhibition suppressed tumour cell invasion, colony formation and promoted radiosensitivity. Conclusion HPV-positive and negative HNSCC have different metabolic profiles which may have potential therapeutic applications.
- Open Access
- 1 May 2018
- Published by Impact Journals, LLC in Oncotarget
- Vol. 9 (33) , 23274-23288
The effects of restricted glycolysis on stem-cell like characteristics of breast cancer cells
// <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Arindam Banerjee1, Pardis Arvinrad1, 2, Matthew Darley1, Stéphanie A. Laversin1, 3, Rachel Parker1, Matthew J.J. Rose-Zerilli1, 6, Paul A. Townsend5, Ramsey I. Cutress1, 4, 6, Stephen A. Beers1, 3, Franchesca D. Houghton2, 6, Charles N. Birts1, 6 and Jeremy P. Blaydes1, 6 1Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton, SO16 6YD, UK 2Centre for Human Development, Stem Cells & Regeneration, Faculty of Medicine, University of Southampton, Southampton, SO16 6YD, UK 3Antibody & Vaccine Group, Faculty of Medicine, University of Southampton, Southampton, SO16 6YD, UK 4University Hospital Southampton, Faculty of Medicine, University of Southampton, Southampton, SO16 6YD, UK 5Division of Molecular and Clinical Cancer Sciences, Manchester Cancer Research Centre, Manchester Academic Health Science Centre, University of Manchester, Manchester, M20 4QL, UK 6Institute for Life Sciences, University of Southampton, Southampton, SO17 1BJ, UK Correspondence to: Jeremy P. Blaydes, email: j.p.blaydes@soton.ac.uk Keywords: breast cancer stem cell-like cells; metabolism; single-cell mRNA-seq; chemoresistance; glycolysis Received: March 01, 2018 Accepted: April 08, 2018 Published: May 01, 2018 ABSTRACT Altered glycolysis is a characteristic of many cancers, and can also be associated with changes in stem cell-like cancer (SCLC) cell populations. We therefore set out to directly examine the effect of glycolysis on SCLC cell phenotype, using a model where glycolysis is stably reduced by adapting the cells to a sugar source other than glucose. Restricting glycolysis using this approach consistently resulted in cells with increased oncogenic potential; including an increase in SCLC cells, proliferation in 3D matrigel, invasiveness, chemoresistance, and altered global gene expression. Tumorigenicity in vivo was also markedly increased. SCLC cells exhibited increased dependence upon alternate metabolic pathways. They also became c-KIT dependent, indicating that their apparent state of maturation is regulated by glycolysis. Single-cell mRNA sequencing identified altered networks of metabolic-, stem- and signaling- gene expression within SCLC-enriched populations in response to glycolytic restriction. Therefore, reduced glycolysis, which may occur in niches within tumors where glucose availability is limiting, can promote tumor aggressiveness by increasing SCLC cell populations, but can also introduce novel, potentially exploitable, vulnerabilities in SCLC cells.
- 1 May 2018
- Published by Impact Journals, LLC in Oncotarget
- Vol. 9 (33) , 23274-23288
Open AccessThe effects of restricted glycolysis on stem-cell like characteristics of breast cancer cells
// <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Arindam Banerjee1, Pardis Arvinrad1, 2, Matthew Darley1, Stéphanie A. Laversin1, 3, Rachel Parker1, Matthew J.J. Rose-Zerilli1, 6, Paul A. Townsend5, Ramsey I. Cutress1, 4, 6, Stephen A. Beers1, 3, Franchesca D. Houghton2, 6, Charles N. Birts1, 6 and Jeremy P. Blaydes1, 6 1Cancer Sciences Unit, Faculty of Medicine, University of Southampton, Southampton, SO16 6YD, UK 2Centre for Human Development, Stem Cells & Regeneration, Faculty of Medicine, University of Southampton, Southampton, SO16 6YD, UK 3Antibody & Vaccine Group, Faculty of Medicine, University of Southampton, Southampton, SO16 6YD, UK 4University Hospital Southampton, Faculty of Medicine, University of Southampton, Southampton, SO16 6YD, UK 5Division of Molecular and Clinical Cancer Sciences, Manchester Cancer Research Centre, Manchester Academic Health Science Centre, University of Manchester, Manchester, M20 4QL, UK 6Institute for Life Sciences, University of Southampton, Southampton, SO17 1BJ, UK Correspondence to: Jeremy P. Blaydes, email: j.p.blaydes@soton.ac.uk Keywords: breast cancer stem cell-like cells; metabolism; single-cell mRNA-seq; chemoresistance; glycolysis Received: March 01, 2018 Accepted: April 08, 2018 Published: May 01, 2018 ABSTRACT Altered glycolysis is a characteristic of many cancers, and can also be associated with changes in stem cell-like cancer (SCLC) cell populations. We therefore set out to directly examine the effect of glycolysis on SCLC cell phenotype, using a model where glycolysis is stably reduced by adapting the cells to a sugar source other than glucose. Restricting glycolysis using this approach consistently resulted in cells with increased oncogenic potential; including an increase in SCLC cells, proliferation in 3D matrigel, invasiveness, chemoresistance, and altered global gene expression. Tumorigenicity in vivo was also markedly increased. SCLC cells exhibited increased dependence upon alternate metabolic pathways. They also became c-KIT dependent, indicating that their apparent state of maturation is regulated by glycolysis. Single-cell mRNA sequencing identified altered networks of metabolic-, stem- and signaling- gene expression within SCLC-enriched populations in response to glycolytic restriction. Therefore, reduced glycolysis, which may occur in niches within tumors where glucose availability is limiting, can promote tumor aggressiveness by increasing SCLC cell populations, but can also introduce novel, potentially exploitable, vulnerabilities in SCLC cells.
- 30 January 2017
- Published by Wiley in International Journal of Cancer
- Vol. 140 (7) , 1564-1570
Novel splice‐switching oligonucleotide promotes BRCA1 aberrant splicing and susceptibility to PARP inhibitor action
Tumors carrying hereditary mutations in BRCA1, which attenuate the BRCA1 DNA damage repair pathway, are more susceptible to dual treatment with PARP inhibitors and DNA damaging therapeutics. Conversely, breast cancer tumors with nonmutated functional BRCA1 are less sensitive to PARP inhibition. We describe a method that triggers susceptibility to PARP inhibition in BRCA1-functional tumor cells. BRCA1 exon 11 is a key for the function of BRCA1 in DNA damage repair. Analysis of the BRCA1 exon 11 splicing mechanism identified a key region within this exon which, when deleted, induced exon 11 skipping. An RNA splice-switching oligonucleotide (SSO) developed to target this region was shown to artificially stimulate skipping of exon 11 in endogenous BRCA1 pre-mRNA. SSO transfection rendered wild-type BRCA1 expressing cell lines more susceptible to PARP inhibitor treatment, as demonstrated by a reduction in cell survival at all SSO concentrations tested. Combined SSO and PARP inhibitor treatment increased γH2AX expression indicating that SSO-dependent skipping of BRCA1 exon 11 was able to promote DSBs and therefore synthetic lethality. In conclusion, this SSO provides a new potential therapeutic strategy for targeting BRCA1-functional breast cancer by enhancing the effect of PARP inhibitors.
- 30 January 2017
- Published by Wiley in International Journal of Cancer
- Vol. 140 (7) , 1564-1570
Novel splice‐switching oligonucleotide promotes BRCA1 aberrant splicing and susceptibility to PARP inhibitor action
Tumors carrying hereditary mutations in BRCA1, which attenuate the BRCA1 DNA damage repair pathway, are more susceptible to dual treatment with PARP inhibitors and DNA damaging therapeutics. Conversely, breast cancer tumors with nonmutated functional BRCA1 are less sensitive to PARP inhibition. We describe a method that triggers susceptibility to PARP inhibition in BRCA1-functional tumor cells. BRCA1 exon 11 is a key for the function of BRCA1 in DNA damage repair. Analysis of the BRCA1 exon 11 splicing mechanism identified a key region within this exon which, when deleted, induced exon 11 skipping. An RNA splice-switching oligonucleotide (SSO) developed to target this region was shown to artificially stimulate skipping of exon 11 in endogenous BRCA1 pre-mRNA. SSO transfection rendered wild-type BRCA1 expressing cell lines more susceptible to PARP inhibitor treatment, as demonstrated by a reduction in cell survival at all SSO concentrations tested. Combined SSO and PARP inhibitor treatment increased γH2AX expression indicating that SSO-dependent skipping of BRCA1 exon 11 was able to promote DSBs and therefore synthetic lethality. In conclusion, this SSO provides a new potential therapeutic strategy for targeting BRCA1-functional breast cancer by enhancing the effect of PARP inhibitors.
- Open Access
- 4 April 2016
- Published by Springer Nature in Oncogenesis
- Vol. 5 (4) , e215
The Bag-1 inhibitor, Thio-2, reverses an atypical 3D morphology driven by Bag-1L overexpression in a MCF-10A model of ductal carcinoma in situ
Mammary MCF-10A cells seeded on reconstituted basement membrane form spherical structures with a hollow central lumen, termed acini, which are a physiologically relevant model of mammary morphogenesis. Bcl-2-associated athanogene 1 (Bag-1) is a multifunctional protein overexpressed in breast cancer and ductal carcinoma in situ. When present in the nucleus Bag-1 is predictive of clinical outcome in breast cancer. Bag-1 exists as three main isoforms, which are produced by alternative translation initiation from a single mRNA. The long isoform of Bag-1, Bag-1L, contains a nuclear localisation sequence not present in the other isoforms. When present in the nucleus Bag-1L, but not the other Bag-1 isoforms, can interact with and modulate the activities of estrogen-, androgen- and vitamin D-receptors. Overexpression of Bag-1 mRNA in MCF-10A is known to produce acini with luminal filling reminiscent of ductal carcinoma in situ. As this mRNA predominantly overexpresses the short isoform of Bag-1, Bag-1S, we set out to examine whether the nuclear Bag-1L isoform is sufficient to drive premalignant change by developing a Bag-1L-overexpressing MCF-10A model. Two clones differentially overexpressing Bag-1L were grown in two-dimensional (2D) and three-dimensional (3D) cultures and compared with an established model of HER2-driven transformation. In 2D cultures, Bag-1L overexpression reduced proliferation but did not affect growth factor responsiveness or clonogenicity. Acini formed by Bag-1L-overexpressing cells exhibited reduced luminal clearing when compared with controls. An abnormal branching morphology was also observed which correlated with the level of Bag-1L overexpression, suggesting further malignant change. Treatment with Thio-2, a small-molecule inhibitor of Bag-1, reduced the level of branching. In summary, 3D cultures of MCF-10A mammary epithelial cells overexpressing Bag-1L demonstrate a premalignant phenotype with features of ductal carcinoma in situ. Using this model to test the small-molecule Bag-1 inhibitor, Thio-2, reveals its potential to reverse the atypical branched morphology of acini that characterizes this premalignant change.
- 4 April 2016
- Published by Springer Nature in Oncogenesis
- Vol. 5 (4) , e215
Open AccessThe Bag-1 inhibitor, Thio-2, reverses an atypical 3D morphology driven by Bag-1L overexpression in a MCF-10A model of ductal carcinoma in situ
Mammary MCF-10A cells seeded on reconstituted basement membrane form spherical structures with a hollow central lumen, termed acini, which are a physiologically relevant model of mammary morphogenesis. Bcl-2-associated athanogene 1 (Bag-1) is a multifunctional protein overexpressed in breast cancer and ductal carcinoma in situ. When present in the nucleus Bag-1 is predictive of clinical outcome in breast cancer. Bag-1 exists as three main isoforms, which are produced by alternative translation initiation from a single mRNA. The long isoform of Bag-1, Bag-1L, contains a nuclear localisation sequence not present in the other isoforms. When present in the nucleus Bag-1L, but not the other Bag-1 isoforms, can interact with and modulate the activities of estrogen-, androgen- and vitamin D-receptors. Overexpression of Bag-1 mRNA in MCF-10A is known to produce acini with luminal filling reminiscent of ductal carcinoma in situ. As this mRNA predominantly overexpresses the short isoform of Bag-1, Bag-1S, we set out to examine whether the nuclear Bag-1L isoform is sufficient to drive premalignant change by developing a Bag-1L-overexpressing MCF-10A model. Two clones differentially overexpressing Bag-1L were grown in two-dimensional (2D) and three-dimensional (3D) cultures and compared with an established model of HER2-driven transformation. In 2D cultures, Bag-1L overexpression reduced proliferation but did not affect growth factor responsiveness or clonogenicity. Acini formed by Bag-1L-overexpressing cells exhibited reduced luminal clearing when compared with controls. An abnormal branching morphology was also observed which correlated with the level of Bag-1L overexpression, suggesting further malignant change. Treatment with Thio-2, a small-molecule inhibitor of Bag-1, reduced the level of branching. In summary, 3D cultures of MCF-10A mammary epithelial cells overexpressing Bag-1L demonstrate a premalignant phenotype with features of ductal carcinoma in situ. Using this model to test the small-molecule Bag-1 inhibitor, Thio-2, reveals its potential to reverse the atypical branched morphology of acini that characterizes this premalignant change.
- 10 March 2015
- Published by Royal Society of Chemistry (RSC) in Organic & Biomolecular Chemistry
- Vol. 13 (15) , 4562-4569
Synthesis and evaluation of a (3R,6S,9S)-2-oxo-1-azabicyclo[4.3.0]nonane scaffold as a mimic of Xaa-trans-Pro in poly-l-proline type II helix conformation
We describe the development of a small-molecule mimic of Xaa-trans-Pro dipeptide in poly-L-proline type II helix conformation, based upon a (3R,6S,9S)-2-oxo-1-azabicyclo[4.3.0]nonane core structure. Stereoselective synthesis of the mimic from L-pyroglutamic acid is achieved in twelve linear steps and 9.9% yield. Configurational and conformational analyses are conducted using a combination of 1H NMR spectroscopy, X-ray crystallography and circular dichroism spectroscopy; and evaluation of the mimic as a promising surrogate dipeptide, in a protein–protein interaction between the SH3 domain of human Fyn kinase (Fyn SH3) and peptidomimetics of its biological ligand, are conducted by 1H-15N HSQC NMR titration experiments.
- 10 March 2015
- Published by Royal Society of Chemistry (RSC) in Organic & Biomolecular Chemistry
- Vol. 13 (15) , 4562-4569
Synthesis and evaluation of a (3R,6S,9S)-2-oxo-1-azabicyclo[4.3.0]nonane scaffold as a mimic of Xaa-trans-Pro in poly-l-proline type II helix conformation
We describe the development of a small-molecule mimic of Xaa-trans-Pro dipeptide in poly-L-proline type II helix conformation, based upon a (3R,6S,9S)-2-oxo-1-azabicyclo[4.3.0]nonane core structure. Stereoselective synthesis of the mimic from L-pyroglutamic acid is achieved in twelve linear steps and 9.9% yield. Configurational and conformational analyses are conducted using a combination of 1H NMR spectroscopy, X-ray crystallography and circular dichroism spectroscopy; and evaluation of the mimic as a promising surrogate dipeptide, in a protein–protein interaction between the SH3 domain of human Fyn kinase (Fyn SH3) and peptidomimetics of its biological ligand, are conducted by 1H-15N HSQC NMR titration experiments.